DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Selective reduction of ADAM10 in brain and cerebrospinal fluid of Alzheimer's disease patients
ADAM10 and ADAM17, members of the membrane-bound disintegrin metalloproteinase (ADAM) family, act as α-secretases in the non-amyloidogenic processing of the amyloid precursor protein. While alterations in ADAM10, the primary α-secretase, have been reported in Alzheimer’s disease (AD), with certain controversy between studies, ADAM17 changes remain less understood. Both enzymes display a complex pattern of expression that includes immature zymogen and mature full-length, assigned as the active form, and soluble cleaved species. We reported for the first time that ADAM10 is present in human cerebrospinal fluid (CSF), and levels of the full-length and soluble fragments decrease in samples from AD patients., This work was supported by grants from Fundació para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (UGP-21-217 to M-S.G-A.); Fondo de Investigaciones Sanitarias (PI22/01329 to J.S-V and PI24/01421 to M-S.G-A)co-funded by the Fondo Europeo de Desarrollo Regional, FEDER “Investing in your future”); CIBERNED (Instituto de Salud Carlos III, Spain); Direcció General de Ciència i Investigació, Generalitat Valenciana (CIAICO/2024/313 to J.S-V). HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023 − 00356, #2022 − 01018 and #2019–02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor. KB is supported by the Swedish Research Council (#2017 − 00915 and #2022 − 00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022–2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden. R-V.P. was supported by São Paulo Research Foundation (FAPESP, grants 2019/20110-1 and #2017/18808-5). A.G-G. was supported by a PhD fellowship (grant CIACIF/2021/426) funded by the Conselleria of Education, Culture, Universities and Employment (Generalitat Valenciana) and co-funded by the European Union through the Fondo Social Europeo (FSE)., Peer reviewed
Proyecto:
ISCIII / Plan Estatal de Investigación Científica PI22-01329
,
ISCIII / Técnica y de Innovación 2021-2023 PI24-01421
,
EC / Plan Estatal de Investigación Científica 101053962
,
EC / Técnica y de Innovación 2021-2023 860197
DOI: http://hdl.handle.net/10261/435776, https://api.elsevier.com/content/abstract/scopus_id/105037796252
HANDLE: http://hdl.handle.net/10261/435776, https://api.elsevier.com/content/abstract/scopus_id/105037796252